Results 91 to 100 of about 692,682 (292)
IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting [PDF]
, 2017 Article full text The full text of this article can be found here. Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please ...
Barnaby Hunt +3 more
core +2 more sources
Diabetes, obesity and metabolism, 2019 To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as add‐on to sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor therapy.
A. Philis-Tsimikas +8 more
semanticscholar +1 more source
Diabetes Care, 2018 OBJECTIVE To compare insulin glargine 300 units/mL (Gla-300) versus insulin degludec 100 units/mL (IDeg-100) in this first head-to-head randomized controlled trial.
J. Rosenstock +11 more
semanticscholar +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims To evaluate the glycaemic outcomes and safety of insulin glargine 300 U/mL (Gla‐300) in Chinese people with uncontrolled type 2 diabetes (T2D) by baseline age and disease duration. Materials and Methods INITIATION was a 24‐week, interventional, single‐arm study where adults with T2D (glycated haemoglobin [HbA1c] 7.5%–11.0%) received Gla ...
Liming Chen +12 more
wiley +1 more source
Clinical studies of glucose variability and hypoglycemia in adult patients with type 1 diabetes [PDF]
, 2011 Diabetes mellitus type 1 is a condition characterized by elevated blood glucose values due to impaired insulin production. This condition is associated with increased morbidity from microand macrovascular complications.
Bragd, Joakim
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims Insulin icodec, the first once‐weekly basal insulin analogue, was approved in China in 2024. Although it has demonstrated robust clinical efficacy, its budget impact remains unknown, and the long‐term cost‐utility within the reimbursement context needs further estimates.
Xichen Tong +3 more
wiley +1 more source
Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats
Endocrine Connections, 2018 It is not fully clarified whether insulin glargine, an analogue with a high affinity for insulin-like growth factor-1 receptor (IGF-1R), increases the risk for cancers that abundantly express IGF-1R such as breast cancer or some types of breast cancer ...
Yusaku Mori +8 more
doaj +1 more source
The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes [PDF]
Srpski Arhiv za Celokupno Lekarstvo, 2016 Introduction. A combination of drugs is required for treatment of obese subjects with diabetes, due to multiple pathogenic mechanisms implicated in the development of both diabetes and obesity. Objective.
Beljić-Živković Teodora +5 more
doaj +1 more source
Perbandingan Profil Penggunaan Terapi Kombinasi Insulin pada Pasien Diabetes Melitus Tipe 2 di Unit Rawat Inap Rumah Sakit Umum Pusat (Rsup) Sanglah [PDF]
, 2013 Kombinasi insulin kerja menengah (Neutral Protamine Hagedorn/NPH) dengan insulin kerja pendek (Regular Human Insulin/RHI) dan kombinasi insulin kerja panjang (insulin glargine) dengan insulin kerja cepat (insulin aspart) adalah jenis kombinasi insulin ...
A, K. I. (Kartika) +2 more
core
Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin [PDF]
, 2014 OBJECTIVE To add to the evidence on comparative long-term effects of insulin analog glargine versus human NPH insulin on the risk for cancer. RESEARCH DESIGN AND METHODS We identified cohorts of initiators of glargine and human NPH without an insulin ...
Blonde, Lawrence +10 more
core +1 more source